Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

Josep Tabernero,Axel Grothey,Eric Van Cutsem,Rona Yaeger,Harpreet Wasan,Takayuki Yoshino,Jayesh Desai,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik-Tobias Arkenau,Pilar García-Alfonso,Elena Elez,Ashwin Gollerkeri,K. Maharry,Janna Christy-Bittel,Scott Kopetz

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

2021

Josep Tabernero
Axel Grothey
Eric Van Cutsem
Rona Yaeger
Harpreet Wasan
Takayuki Yoshino
Jayesh Desai
Fortunato Ciardiello
Fotios Loupakis
Yong Sang Hong
Neeltje Steeghs
Tormod Kyrre Guren
Hendrik-Tobias Arkenau
Pilar García-Alfonso
Elena Elez
Ashwin Gollerkeri
K. Maharry
Janna Christy-Bittel
Scott Kopetz

PURPOSEBEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E–mutant metastatic ...

Keywords:

Medicine
Oncology
Internal medicine
Colorectal cancer
Encorafenib
Irinotecan
Cetuximab
FOLFIRI
previously treated
Binimetinib
BRAF V600E

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations